A Phase 1a/1b Study of LY3537982 in Patients with KRAS G12C-Mutant Advanced Solid Tumors

Brief description of study

The purpose of the study is to determine and evaluate the safety, tolerability, and preliminary efficacy of oral LY3537982 as monotherapy and as part of combination therapy in patients with KRAS G12C-mutant advanced solid tumor types. We want to know the recommended dose for LY3537982 monotherapy and we want to test the dose in different cohorts. The study drug LY3537982 is investigational, which means that it has not been approved by the U.S Food and Drug Administration (FDA), the health authority that gives approval for new medicines to be prescribed in the United States, but the FDA has given its permission to test this agent in the current trial.


Clinical Study Identifier: s21-00538
ClinicalTrials.gov Identifier: NCT04956640
Principal Investigator: Joshua K Sabari.
Other Investigators: Nila Theresa De La Rosa, Elaine Shum, Scot Niglio, Nitish Mehta, Vamsidhar Velcheti, Eneil De La Pena, Janice Mehnert, Laura Palazzolo, Jeffrey S. Weber, Jessica Wang, Jonathan B Kahn, Danny Perlaza, Keriann M Scavone, Marissa Rybstein, Nina Beri, Avital Benson, Caitlin Elizabeth Ryan, David R. Wise, Elka R Travis, Salman Rafi Punekar, Sally Lau, Jeffrey G Schneider, Samantha VanMaanen, Kristen Spencer, James Newman, Kathleen M Madden, Douglas K Marks.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.